ArriVent BioPharma (AVBP) Research & Development (2023 - 2026)
ArriVent BioPharma (AVBP) posted Research & Development of $42.34 million for Q2 2026, up 52.7% from $27.72 million a year earlier and up 12.6% from the prior quarter.
Powered by 
Analysis
ArriVent BioPharma (AVBP) Research & Development (2023 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, Research & Development at ArriVent BioPharma was $144.3 million, up 11.6% year-over-year; for FY2025, it came in at $153.35 million, up 94.1% from FY2024.
- In prior years, ArriVent BioPharma's Research & Development was $79 million in FY2024 (+21.8%) and $64.88 million in FY2023.
- The Q2 2026 figure stands as the highest quarterly Research & Development since Q1 2025.
- On a year-over-year basis, Research & Development increased in seven of the last eight quarters, with growth averaging 57.9%.
- The strongest year-over-year quarter for Research & Development in the past five years was Q1 2025, with growth of 261.1%; the weakest was Q1 2026, with a decline of 38.6%.
- According to Business Quant data, Research & Development for the three prior quarters was $37.62 million (Q1 2026), $32.18 million (Q4 2025) and $32.17 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 3.02 Bn |
| 10 | ArriVent BioPharma | 690.85 Mn | -714.69 Mn | - | 38.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 38.90 Mn |
| Jun 30, 2026 | 42.34 Mn |
| Mar 31, 2026 | 37.62 Mn |
| Dec 31, 2025 | 32.18 Mn |
| Sep 30, 2025 | 32.17 Mn |
| Jun 30, 2025 | 27.72 Mn |
| Mar 31, 2025 | 61.29 Mn |
| Dec 31, 2024 | 20.16 Mn |
| Sep 30, 2024 | 20.09 Mn |
| Jun 30, 2024 | 21.78 Mn |
| Mar 31, 2024 | 16.98 Mn |
| Dec 31, 2023 | 20.01 Mn |
| Sep 30, 2023 | 14.28 Mn |
| Jun 30, 2023 | 20.36 Mn |
| Mar 31, 2023 | 10.24 Mn |
API Access
ArriVent BioPharma Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=AVBP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "AVBP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=AVBP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();